STOCK TITAN

Bionano Genomics (NASDAQ: BNGO) GC lists 15,000 stock option shares

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Bionano Genomics, Inc. insider Jonathan V. Dixon, the company’s General Counsel, holds a stock option classified as a derivative security. The option covers 15,000 shares of Common Stock at an exercise price of $1.1200 per share and expires on August 2, 2036.

The shares subject to this option vest 50% on each of the first and second anniversaries of the vesting commencement date, in each case subject to Mr. Dixon’s Continuous Service under the company’s 2018 Plan.

Positive

  • None.

Negative

  • None.
Insider Dixon Jonathan V.
Role General Counsel
Type Security Shares Price Value
holding Stock Option (Right to Buy) F1 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 15,000 shares (Direct)
Footnotes (1)
  1. F1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.
Underlying Shares 15000.0000 shares Common Stock underlying reported stock option
Exercise Price $1.1200 per share Exercise price of Stock Option (Right to Buy)
Expiration Date 2036-08-02 Expiration of the reported stock option
Vesting Tranche 1 50% of option Vests on first anniversary of vesting commencement date
Vesting Tranche 2 50% of option Vests on second anniversary of vesting commencement date
Stock Option (Right to Buy) financial
"Security titled "Stock Option (Right to Buy)" over common stock"
Continuous Service financial
"subject to the Reporting Person's Continuous Service under the 2018 Plan"
vesting commencement date financial
"vest 50% on each of the first and second anniversaries of the vesting commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
2018 Plan financial
"as defined in the Company's 2018 Plan governing the option terms"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider role does Jonathan V. Dixon hold at Bionano Genomics (BNGO)?

Jonathan V. Dixon is the General Counsel of Bionano Genomics, Inc. He is reported as an officer, not a director or 10% owner, and his disclosed beneficial ownership relates to an option over the company’s common stock.

How many BNGO shares are covered by Jonathan Dixon’s reported stock option?

Jonathan Dixon’s reported stock option covers 15,000.0000 underlying shares of Bionano Genomics common stock. These shares are tied to a single option position disclosed as a derivative security with direct ownership.

What is the exercise price and expiration date of Jonathan Dixon’s BNGO stock option?

The stock option has an exercise price of $1.1200 per share and an expiration date of 2036-08-02. This defines the price at which he may purchase the underlying shares and the last date on which the option can be exercised.

How does Jonathan Dixon’s BNGO stock option vest over time?

The option vests in two equal tranches of 50% of the total shares each. Half vests on the first anniversary and half on the second anniversary of the vesting commencement date, subject to his Continuous Service under the company’s 2018 Plan.

Is Jonathan Dixon’s ownership in BNGO common stock direct or indirect?

The reported derivative position is held with direct ownership. The option is listed as a direct holding, with no indication of indirect ownership through entities such as trusts, LLCs, or family members in the disclosure.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Dixon Jonathan V.

(Last)(First)(Middle)
C/O BIONANO GENOMICS, INC.
9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026
3. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
General Counsel
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (1)08/02/2036Common Stock15,000$1.12D
Explanation of Responses:
1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.
/s/ Jonathan V. Dixon, Attorney-in-Fact08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)